{
    "title": "Companies in Alzheimer's race after US nod for Eisai/Biogen drug",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12276271/Companies-Alzheimers-race-US-nod-Eisai-Biogen-drug.html",
    "date": "2023-07-07",
    "keywords": [
        "trial",
        "inc",
        "midstage",
        "drug",
        "brain",
        "disease",
        "therapy",
        "development",
        "stage",
        "betaamyloid",
        "latestage",
        "sa",
        "inhibitor",
        "ltd",
        "biogen",
        "incs",
        "leqembi",
        "treatment",
        "food",
        "approval",
        "thursday",
        "milestone",
        "following",
        "list",
        "memoryrobbing",
        "company",
        "mechanism",
        "amp",
        "indication",
        "target",
        "toxic",
        "protein",
        "plaque",
        "decline",
        "biovie",
        "molecule",
        "mild",
        "resistance",
        "ab",
        "science",
        "study",
        "kinase",
        "neuroinflammati",
        "annovis",
        "buntanetap",
        "bio",
        "midtolatestage",
        "cognition",
        "therapeuti",
        "bind",
        "mildtomoderate",
        "attachment",
        "coya",
        "inhibit",
        "cs",
        "function",
        "actinogen",
        "xanamem",
        "production",
        "mildmoderate",
        "hormone",
        "cortisol",
        "impairment",
        "ac",
        "immune",
        "tomid",
        "immunotherapy",
        "oligonucleotide",
        "earlystage",
        "cell",
        "progression",
        "reporting",
        "pratik",
        "jain",
        "mariam",
        "sunny",
        "bengaluru",
        "editing",
        "maju",
        "samuel"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}